Central Nervous System News and Research

RSS

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Among full-term newborns with moderate or severe hypoxic ischemic encephalopathy (damage to cells in the central nervous system from inadequate oxygen), receiving deeper or longer duration cooling did not reduce risk of neonatal intensive care unit death, compared to usual care, according to a study in the December 24/31 issue of JAMA.

24 Dec 2014

Muscle spindle sensory feedback promotes functional recovery after spinal cord injury

After an incomplete spinal cord injury, the body can partially recover basic motor function. So-called muscle spindles and associated sensory circuits back to the spinal cord promote the establishment of novel neuronal connections after injury.

23 Dec 2014

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

New UCLA research indicates that lost memories can be restored. The findings offer some hope for patients in the early stages of Alzheimer's disease.

23 Dec 2014

Scientists discover genetic pathway responsible for brain development

Scientists at A*STAR's Institute of Medical Biology and Institute of Molecular and Cellular Biology have identified a genetic pathway that accounts for the extraordinary size of the human brain.

19 Dec 2014

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Clinatec chairman receives Lifetime Achievement Award for breakthrough research on Parkinson's disease

Prof. Alim-Louis Benabid, board chairman of Clinatec - The Edmond J. Safra Biomedical Research Center, received the Lifetime Achievement award on Dec. 13 from the North American Neuromodulation Society (NANS) for his work in developing deep brain stimulation to relieve symptoms in Parkinson’s disease patients.

16 Dec 2014

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Back pain is exceptionally common. In fact, to not experience back pain at some point of your life would be thoroughly abnormal. Experiencing back pain is like becoming tired or becoming sad; we don’t necessarily like it, but it’s perfectly common.

14 Dec 2014

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies.

14 Dec 2014

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence of impaired mental function.

14 Dec 2014

Abbott acquires control of Veropharm for $305 million

Abbott today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer.

12 Dec 2014

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active.

11 Dec 2014

Researchers develop new how-to exercise program to help MS people stay more physically active

Fatigue and pain, along with other symptoms, prevent many people with multiple sclerosis (MS) from exercising. But a new how-to guide for a home-based exercise program, tested by researchers at Case Western Reserve University's nursing school and the Lerner Research Institute at the Cleveland Clinic, offers a way for people with MS to stay more physically active.

11 Dec 2014

Study reveals how the human brain heals itself after surgical removal of brain tumor

An interdisciplinary team of neuroscientists and neurosurgeons from the University of Rochester has used a new imaging technique to show how the human brain heals itself in just a few weeks following surgical removal of a brain tumor.

11 Dec 2014

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children's Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

10 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

McMaster University researchers identify hormone that contributes to obesity, diabetes

Researchers from McMaster University have identified an important hormone that is elevated in obese people and contributes to obesity and diabetes by inhibiting brown fat activity.

8 Dec 2014

New chemical compound shows promise in restoring function lost to spinal cord injury

Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested.

4 Dec 2014

Tobacco smoke toxin could increase pain in people with spinal cord injury

A neurotoxin called acrolein found in tobacco smoke that is thought to increase pain in people with spinal cord injury has now been shown to accumulate in mice exposed to the equivalent of 12 cigarettes daily over a short time period.

4 Dec 2014

New book urges nurses to speak up and be heard

Nurses Making Policy: From Bedside to Boardroom (Springer Publishing, 2014) implores nurses to speak up and be heard, from the hospital corridors to the floors of Congress.

2 Dec 2014

Central Nervous System News and Research

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Muscle spindle sensory feedback promotes functional recovery after spinal cord injury

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

Scientists discover genetic pathway responsible for brain development

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Clinatec chairman receives Lifetime Achievement Award for breakthrough research on Parkinson's disease

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Anavex Life Sciences qualifies to trade on OTCQX

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Abbott acquires control of Veropharm for $305 million

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

Researchers develop new how-to exercise program to help MS people stay more physically active

Study reveals how the human brain heals itself after surgical removal of brain tumor

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

McMaster University researchers identify hormone that contributes to obesity, diabetes

New chemical compound shows promise in restoring function lost to spinal cord injury

Tobacco smoke toxin could increase pain in people with spinal cord injury

New book urges nurses to speak up and be heard

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News